<PAGE> 1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
AMENDMENT NO. 1 TO FORM 10-K
(MARK ONE)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ________ TO ________
COMMISSION FILE NUMBER 0-21696
ARIAD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 22-3106987
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
26 LANDSDOWNE STREET, CAMBRIDGE, MASSACHUSETTS 02139-4234
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (617) 494-0400
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
COMMON STOCK, $.001 PAR VALUE
COMMON STOCK PURCHASE WARRANTS
RIGHTS TO PURCHASE SERIES A PREFERRED STOCK
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
YES [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
The number of shares of the registrant's Common Stock outstanding as of
March 10, 1999: 21,992,880.
The number of Common Stock Purchase Warrants outstanding as of March 10,
1999: 2,125,225.
The aggregate market value of the voting stock held by nonaffiliates of the
registrant was approximately $30 million as of March 10, 1999, based on the last
reported sales price of the registrant's Common Stock on the Nasdaq National
Market on such date.
================================================================================
<PAGE> 2
The undersigned registrant hereby amends and restates its Annual Report on
Form 10-K for the year ended December 31, 1998 to include Items 10, 11, 12 and
13 of Part III and as otherwise set forth on the pages attached hereto.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
INFORMATION REGARDING DIRECTORS
The Board of Directors currently consists of ten members, classified into
three classes. At each Annual Meeting of the Stockholders, the term for one
class of directors expires and directors are elected for a full term of three
years to succeed the directors of such class. Set forth below is certain
biographical information for each of the three individuals nominated by the
Board of Directors for election as Class 2 Directors at the next Annual Meeting
of the Stockholders, as well as for each of the continuing Class 1 and Class 3
Directors whose terms expire either at the Annual Meeting of the Stockholders in
2000 or 2001, or at such time as such director's successor is duly elected and
qualified. All of the other companies listed as companies in which certain
directors hold directorships are publicly traded companies.
NOMINEES AS CLASS 2 DIRECTORS
(TERM TO EXPIRE 2002)
Philip Felig, M.D., 62, a Director of ARIAD since October 1991, is
currently in medical practice specializing in endocrinology and diabetes as an
Attending Physician on the Senior Medical Staff at Lenox Hill Hospital. From
1986 to 1987, he was Chief Executive Officer of Sandoz Pharmaceuticals
Corporation and from 1984 to 1987, President of the Sandoz Research Institute.
Jay R. LaMarche, 52, has served as Chief Financial Officer, Treasurer and a
Director of ARIAD since January 1992. Mr. LaMarche has served as Executive Vice
President since March 1997 and as Senior Vice President, Finance from January
1992 to February 1997. Prior to joining ARIAD, he was Chief Financial Officer
and a Director of ChemDesign Corporation, a fine chemicals manufacturer, where
he served in several capacities, most recently as Executive Vice President.
Joel S. Marcus, 51, a Director of ARIAD since February 1995, is Chief
Executive Officer of Alexandria Real Estate Equities, Inc. Mr. Marcus is a
founder and principal of Health Science Capital Partners, which invests in
healthcare related companies. From 1986 to 1994, Mr. Marcus was a partner with
Brobeck, Phleger & Harrison, LLP, a leading technology law firm (and its
predecessor).
<PAGE> 3
CONTINUING CLASS 3 DIRECTORS
(TERM TO EXPIRE 2000)
Harvey J. Berger, M.D., 48, is the principal founder of ARIAD and has
served as the Company's Chairman of the Board, President and Chief Executive
Officer since April 1991. From 1986 to 1991, Dr. Berger held a series of senior
management positions at Centocor, Inc., a biotechnology company, most recently
as Executive Vice President and President of the Research and Development
Division. Dr. Berger currently is a Lecturer in the Division of Health Sciences
and Technology at the Massachusetts Institute of Technology and the Harvard
Medical School. He also has held senior academic and administrative appointments
at Emory University, Yale University and the University of Pennsylvania and was
an Established Investigator of the American Heart Association.
Vaughn D. Bryson, 60, a Director of ARIAD since February 1995, is President
of Life Science Advisors, Inc. Mr. Bryson was a thirty-two year employee of Eli
Lilly & Co. ("Lilly") and served as President and Chief Executive Officer of
Lilly from 1991 to 1993. He served as Executive Vice President from 1986 until
1991. He also served as a member of Lilly's Board of Directors from 1984 until
his retirement in 1993. Mr. Bryson was Vice Chairman of Vector Securities
International Inc. from April 1994 to December 1996. He also is a Director of
Chiron Corporation, Fusion Medical Technologies, Inc., Perclose, Inc. and
Quintiles Transnational Corporation.
Sandford D. Smith, 52, a Director of ARIAD since October 1991 and Vice
Chairman since January 1999, is President, Therapeutics International, Genzyme
Corporation. Previously, from May 1996 to September 1996, he was Vice President
and General Manager, Specialty Therapeutics and International Group, Genzyme
Corporation. Mr. Smith was President and Chief Executive Officer and a Director
of the Repligen Corporation from June 1986 to March 1996. Mr. Smith previously
held a number of positions with the Bristol-Myers Company from 1977 to 1986,
including, most recently, Vice President of Corporate Development and Planning
for the United States Pharmaceutical and Nutritional Group. Mr. Smith is also a
Director of CSP, Inc.
Raymond S. Troubh, 73, a Director of ARIAD since October 1991, has been a
financial consultant for more than the past five years. He was a general partner
of Lazard Freres & Co., an investment banking firm, and a former governor of the
American Stock Exchange. Mr. Troubh is a Director of Becton, Dickinson and
Company, Diamond Offshore Drilling, Inc., Foundation Health Systems, Inc.,
General American Investors Company, Inc., Olsten Corporation, Starwood Hotels &
Resorts, Inc., Triarc Companies, Inc., WHX Corporation and a trustee of Petrie
Stores Liquidating Trust.
CONTINUING CLASS 1 DIRECTORS
(TERM TO EXPIRE 2001)
Joan S. Brugge, Ph.D., 49, a Director of ARIAD since February 1995, is
Professor of Cell Biology at Harvard Medical School. Dr. Brugge served as Senior
Vice President, Exploratory Research at ARIAD from October 1996 through July
1997 and as Senior Vice President, Research - Biology from May 1992 to September
1996 and as Scientific Director of ARIAD from May 1992 to February 1997. From
1989 to 1992, Dr. Brugge was a
2
<PAGE> 4
Professor of Microbiology at the University of Pennsylvania School of Medicine
and an Investigator of the Howard Hughes Medical Institute. Dr. Brugge currently
serves on the Medical Advisory Board of the Howard Hughes Medical Institute and
the Advisory Committee to the Director and Board of Scientific Advisors of the
National Cancer Institute.
John M. Deutch, Ph.D., 60, a Director of ARIAD since March 1997, is an
Institute Professor at the Massachusetts Institute of Technology. He has
previously served as Director of Central Intelligence, Deputy Secretary of
Defense and Undersecretary of Defense (Acquisition and Technology), as well as
Provost of the Massachusetts Institute of Technology, Dean of the School of
Science, Chairman of the Department of Chemistry and the Karl Taylor Compton
Professor of Chemistry. He has numerous publications in physical chemistry. Mr.
Deutch is a Director of Citigroup, CMS Energy, Cummins Engine Company, Inc. and
Schlumberger Ltd.
Ralph Snyderman, M.D., 59, a Director of ARIAD since June 1998, has been
Chancellor for Health Affairs, Dean, School of Medicine at Duke University, and
President and CEO of Duke University Health System since March 1989. He was
formerly Senior Vice President of Medical Research and Development at Genentech,
Inc. from January 1987 to May 1989. Dr. Snyderman also serves on the Board of
Directors of Proctor and Gamble, Inc.
EXECUTIVE OFFICERS
The following table sets forth certain information regarding the executive
officers of the Company:
NAME AGE OFFICE OR POSITIONS HELD
- ---- --- ------------------------
Harvey J. Berger, M.D. 48 Chairman of the Board, President and
Chief Executive Officer
Jay R. LaMarche 52 Executive Vice President and Chief Financial
Officer
Laurie A. Allen, Esq. 38 Senior Vice President, Corporate Development
and Legal Affairs, General Counsel and
Secretary
John D. Iuliucci, Ph.D. 56 Senior Vice President, Drug Development
Manfred Weigele, Ph.D. 66 Senior Vice President, Chief Scientific Officer
Mark J. Zoller, Ph.D. 45 Senior Vice President, Genomics and Scientific
Director, Hoechst-ARIAD Genomics Center, LLC
For biographical information on Dr. Berger and Mr. LaMarche, see "Information
Regarding Directors."
Laurie A. Allen, Esq. has served as Senior Vice President, Corporate
Development and Legal Affairs, General Counsel and Secretary since January 1999.
Prior to joining ARIAD, she was a partner with Brobeck, Phleger and Harrison,
LLP, a leading technology law firm, from January 1996 to December 1998. She was
an associate with Brobeck, Phleger & Harrison, LLP from February 1991 to
December 1995 and with Pettit & Martin from September 1989 to January 1991. Ms.
Allen received her L.L.M. degree in taxation from New York University and her
J.D. degree from Emory University School of Law. She received her A.B. degree in
History from the
3
<PAGE> 5
University of California, Los Angeles.
John D. Iuliucci, Ph.D. has served as Senior Vice President, Drug
Development since January 1999. Dr. Iuliucci also served as Vice President, Drug
Development from October 1996 to December 1998, and Vice President, Preclinical
Development of ARIAD from June 1992 to September 1996. Prior to joining ARIAD,
Dr. Iuliucci was Director of Preclinical Pharmacology and Toxicology at
Centocor, Inc. from 1984 to 1992. From 1975 to 1984, Dr. Iuliucci headed the
Drug Safety Evaluation Department at Adria Laboratories. He was a Senior
Toxicologist at the Warner-Lambert Pharmaceutical Research Institute from 1972
to 1975. Dr. Iuliucci received a B.S. degree in Pharmacy and M.S. and Ph.D.
degrees in Pharmacology from Temple University.
Manfred Weigele, Ph.D. has served as Senior Vice President and Chief
Scientific Officer since March 1999. Dr. Weigele also served as Senior Vice
President, Physical and Chemical Sciences from October 1996 to February 1999 and
as Senior Vice President, Research - Chemistry of ARIAD from October 1991 to
September 1996. Prior to joining ARIAD, from 1985 to 1991, Dr. Weigele was a
Vice President and Group Director of Chemistry Research for Hoffmann-LaRoche
Inc., where he directed chemistry research. He joined Hoffmann-LaRoche, a
worldwide pharmaceuticals company, in 1965. Dr. Weigele received his
undergraduate training at Technische Universitat in Braunschweig, Germany and
his Ph.D. degree from the University of Wisconsin.
Mark J. Zoller, Ph.D. has served as Senior Vice President, Genomics since
November 1998 and as Scientific Director of the Hoechst-ARIAD Genomics Center,
LLC since April 1997. Dr. Zoller also served as Vice President, Genomics from
April 1997 to October 1998, Vice President, Drug Discovery - Signal Transduction
from October 1996 to March 1997 and Vice President, Research - Molecular Biology
from November 1994 to September 1996. Previously, he served as Director,
Molecular Biology for ARIAD from June 1992 to October 1994. Prior to joining
ARIAD, he was a Senior Scientist and group leader of Genentech, Inc. Previously,
Dr. Zoller was a Senior Staff Investigator at the Cold Spring Harbor Laboratory
where he focused on the development of molecular genetic systems to study
protein kinases. Dr. Zoller received his Ph.D. degree in Chemistry from the
University of California, San Diego and was a Postdoctoral Fellow in Molecular
Biology at the University of Vancouver, Canada.
SECTION 16 FILINGS
Section 16(a) of the Exchange Act requires the Company's directors,
executive officers and beneficial owners of more than 10% of the Company's
Common Stock to file reports of ownership and changes of ownership with the
Commission on Forms 3, 4 and 5. The Company believes that during the fiscal year
ended December 31, 1998 its directors, executive officers and beneficial owners
of more than 10% of the Company's Common Stock complied with all applicable
filing requirements. In making these disclosures, the Company has relied solely
on information filed with the Commission.
4
<PAGE> 6
ITEM 11. EXECUTIVE COMPENSATION
The following table sets forth aggregate amounts of compensation paid or
accrued by the Company for the years ended December 31, 1998, 1997 and 1996, for
services rendered in all capacities, by each of the Company's Chief Executive
Officer, the four most highly compensated executive officers other than the
Chief Executive Officer and one additional individual for whom disclosure would
have been provided but for the fact that such individual was not serving as an
executive officer at December 31, 1998.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM COMPENSATION
ANNUAL COMPENSATION(1) ----------------------
----------------------- NUMBER OF SECURITIES ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY UNDERLYING OPTIONS COMPENSATION(2)
- --------------------------- ---- ----------------------- ---------------------- ---------------
<S> <C> <C> <C> <C>
Harvey J. Berger, M.D. 1998 $300,000 100,000 $3,200
Chairman, President and 1997 300,000 -- --
Chief Executive Officer 1996 220,000 44,000 --
Jay R. LaMarche 1998 215,000 50,000 3,200
Executive Vice President and 1997 215,000 -- --
Chief Financial Officer 1996 170,000 34,000 --
Manfred Weigele, Ph.D. 1998 173,654 50,000 --
Senior Vice President, 1997 215,000 -- --
Physical and Chemical Sciences 1996 170,000 34,000 --
Mark J. Zoller, Ph.D. 1998 165,000 50,000 3,200
Senior Vice President, 1997 165,000 -- --
Genomics and Scientific 1996 145,000 21,000 --
Director
Michael Gilman, Ph.D.(3) 1998 215,000 50,000 3,200
1997 215,000 -- --
1996 159,651 80,000 --
Charles C. Cabot III(4) 1998 194,327 50,000 3,200
1997 215,000 -- --
1996 170,000 44,000 --
</TABLE>
- ----------
(1) Other annual compensation is not presented, as the cost did not exceed the
lesser of $50,000 or 10% of the total salary reported for any of the named
executive officers.
(2) The amounts listed are for the Company's matching contributions under its
401(k) Plan. Does not include cash bonuses issued in the form of options to
purchase designated mutual funds, which options were awarded in lieu of
such bonuses in March 1998 under the ARIAD Pharmaceuticals, Inc. 1997
Executive Compensation Plan and all of which options vest in four equal
annual installments commencing one year after the date of the award.
Options with a value of $55,000 were issued to each of Mr. LaMarche, Dr.
Weigele and Dr. Gilman and options with a value of $25,000 were issued to
Dr. Zoller.
(3) Mr. Gilman's employment as Executive Vice President and Chief Scientific
Officer terminated in March 1999.
(4) Mr. Cabot's employment as Executive Vice President and Chief Operating
Officer terminated in November 1998.
5
<PAGE> 7
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Compensation and Stock Option Committee is comprised of Dr. Felig and
Messrs. Smith and Troubh. On December 1, 1998, pursuant to the 1994 Director
Plan, the Company granted to each member of the committee an option to purchase
10,000 shares of Common Stock at $1.94 per share.
EMPLOYMENT AGREEMENTS
Dr. Berger, Chief Executive Officer, President and Chairman of the Board of
Directors of the Company, has an employment agreement with the Company which
commenced in January 1992 and terminates in December 2001. The agreement
provides that he shall be employed as the Chief Executive Officer and President
of the Company, shall be nominated for election to the Board of Directors, serve
as Chairman of the Board and receive an annual base salary of $300,000 for 1998,
increasing each year by at least 10% of the preceding year's base salary. Dr.
Berger is eligible each year to receive a discretionary bonus, determined by the
Board of Directors, of up to 50% of his annual base salary. Dr. Berger's
employment agreement is automatically renewable for successive three-year terms
unless terminated by either party. If the Company fails to renew the employment
agreement, it is obligated to pay Dr. Berger, in addition to his compensation
for the remainder of the term, a lump sum payment equal to two times Dr.
Berger's annual salary for the final year of the term and to provide for the
immediate exercisability of all stock options and other equity rights.
Dr. Berger's employment agreement provides that, if the agreement is
terminated by either party upon the occurrence of certain events including, (i)
a sale or merger of the Company (or stockholder approval of a merger agreement)
or an acquisition of a substantial equity interest in the Company by a person or
group of persons, (ii) if Dr. Berger is not elected to membership on the Board
of Directors, named as Chairman or designated as Chief Executive Officer or
ceases to be the highest ranking executive officer of the Company or ceases to
control personnel decisions with respect to the Company's employees, (iii) if
the Company is in material breach of the terms of his employment agreement, (iv)
if the Company is bankrupt or insolvent or (v) if the Company terminates Dr.
Berger's employment agreement without cause, (1) the Company will pay Dr. Berger
the greater of (x) any remaining salary payable during the term of the agreement
plus the maximum possible bonus for each year remaining in the term (taking into
account, in both cases, future 10% increases in salary and (y) an amount equal
to twice his current annual salary and maximum bonus for the current year of
employment (the "Severance Payment") and (2) all of his stock options, stock
awards and similar equity rights will immediately vest and become exercisable.
The Company is not obligated to make the Severance Payment if it discharges Dr.
Berger for cause. If the vesting of certain benefits and the payment of certain
amounts by the Company to Dr. Berger are treated as payments in the nature of
compensation that are contingent on a "change in control" (within the meaning of
Section 280G of the Internal Revenue Code of 1986, as amended (the "Code")), the
deductibility of such payments could, depending upon the aggregate amount of
such payments, be disallowed pursuant to Section 280G of the Code and an excise
tax could be imposed on Dr. Berger pursuant to Section 4999 of the Code for
which he would, pursuant to the employment agreement, be indemnified by the
Company on a net after-tax basis. The employment agreement contains a
noncompetition provision that is effective during the term of the agreement and,
if Dr. Berger is terminated for cause, for a period of one year following the
date of termination.
6
<PAGE> 8
The Company has also entered into employment agreements with Mr. LaMarche
and Ms. Allen, as well as Drs. Iuliucci and Zoller. The agreements provide for
employment at each such executive's present position through December 2000 for
Mr. LaMarche, December 2001 for Ms. Allen and December 1999 for Drs. Iuliucci
and Zoller at their annual base salaries of $220,000, $215,000, $200,000 and
$210,000, respectively, increasing each year by an amount to be determined by
the Board of Directors. In addition, each executive is eligible each year to
receive a discretionary bonus, to be determined by the Board of Directors, of up
to 30% of his or her annual base salary. The agreements are renewable for
successive one-year terms with the mutual consent of the parties.
These agreements provide that: (i) upon a change of control of the Company,
such officers will be entitled to receive, upon termination by the officer
within 90 days after the change in control, any remaining salary payable during
the term or six months' salary whichever is shorter, and all stock options held
by such officers will immediately vest and become exercisable; and (ii) upon
termination by the Company, without cause, such officer will be entitled to
receive his current salary for the remaining period of the applicable term and
all outstanding options that would have vested during such term shall vest
immediately.
OPTION GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
Potential
Realizable Value
Percent of at Assumed Annual
Number of Total Rates of Stock
Securities Options Price Appreciation
Underlying Granted to for Option Term
Options Employees in Exercise Expiration ------------------
Name Granted(1) Fiscal Year Price Date 5%($) 10%($)
- ---- ---------- ------------ -------- ---------- -------------------
<S> <C> <C> <C> <C> <C> <C>
Harvey J. Berger, M.D. 100,000 8.2% $3.88 03/05/08 $243,697 $617,575
Jay R. LaMarche 50,000 4.1% $4.31 02/02/08 153,185 343,691
Manfred Weigele, Ph.D. 50,000 4.1% $4.31 02/02/08 153,185 343,691
Mark J. Zoller, Ph.D. 20,000 1.6% $4.31 02/02/08 61,274 137,476
30,000 2.5% $2.69 09/10/08 57,282 128,519
Michael Gilman, Ph.D. 50,000 4.1% $4.31 02/02/08 153,185 343,691
Charles C. Cabot III 50,000 4.1% $4.31 02/02/08 153,185 343,691
</TABLE>
7
<PAGE> 9
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION
VALUES
<TABLE>
<CAPTION>
No. of Securities
Underlying Value of Unexercised
Unexercised Options In-the-Money Options at
at Fiscal Year End(#) Fiscal Year End($)(4)
Shares --------------------- -----------------------
Acquired on Value Exercisable/ Exercisable/
Name Exercise (#) Realized($) Unexercisable Unexercisable
- ---- ----------- ----------- --------------------- -----------------------
<S> <C> <C> <C> <C>
Harvey J. Berger, M.D. -- -- 354,714/75,000(1)(2) $4,375/0
178,571/0(3) --
Jay R. LaMarche -- -- 105,857/37,500(1) 2,537/0
89,285/0(3) --
Manfred Weigele, Ph.D. -- -- 111,857/37,500(1) 3,062/0
89,285/0(3) --
Mark J. Zoller, Ph.D. -- -- 124,928/45,000(1) 1,750/0
Michael Gilman, Ph.D. -- -- 92,500/65,000(1) 656/0
100,000/0(3) --
Charles C. Cabot III -- -- 111,857/37,500(1) 3,062/0
89,285/0(3) --
</TABLE>
- ----------
(1) Options to purchase shares of Common Stock of the Company.
(2) Includes options to purchase 235,714 shares held by The Berger Family
Trust.
(3) Options to purchase Common Stock of ARIAD Gene Therapeutics, Inc.
(4) Based upon a fair market value of $1.69 per share of Common Stock, which
was the closing price of a share of Common Stock on the Nasdaq National
Market on December 31, 1998.
401(k) PLAN
Effective January 1, 1993, the Board of Directors adopted the ARIAD
Retirement Savings Plan (the "401(k) Plan") which is intended to qualify under
Section 401(k) of the Code covering all of the Company's eligible employees.
Pursuant to the 401(k) Plan, employees may elect to defer, in the form of
contributions to the 401(k) Plan, from 1% to 15% of their current compensation
up to the statutorily prescribed annual limit ($10,000 in 1998) and have the
amount of the reduction contributed to the 401(k) Plan. Effective July 1, 1997,
the Company agreed to match 50% of the first 4% of compensation that eligible
employees contribute to the 401(k) plan, as defined. Employer matching
contributions to the 401(k) plan amounted to $156,000 for the year ended
December 31, 1998.
8
<PAGE> 10
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of April 23, 1999 certain information
with respect to (i) each person (including any "group" as defined in Section
13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange
Act")) known to the Company to own beneficially more than 5% of the Voting
Stock, (ii) each director of the Company, (iii) each executive officer named in
the Summary Compensation Table under "Executive Compensation" and (iv) all
directors and executive officers as a group. In accordance with the rules
promulgated by the Securities and Exchange Commission (the "Commission"), such
ownership includes shares currently owned, as well as shares that the named
person has the right to acquire within 60 days, including, but not limited to,
shares that the named person has the right to acquire through the exercise of
any option, warrant or right or through the conversion of a security. The
percentages set forth on the table assume conversion of all outstanding Series B
Preferred Stock and Series C Preferred Stock into Common Stock.
Except as otherwise indicated, (i) the stockholders listed in the table
have sole voting and investment powers with respect to the Voting Stock shown as
beneficially owned, and (ii) the title of class of the shares held by the
stockholders listed in the table is Common Stock.
<TABLE>
<CAPTION>
NUMBER OF SHARES
NAME AND ADDRESS BENEFICIALLY OWNED PERCENTAGE
- ---------------- ------------------ ----------
<S> <C> <C>
Hoechst Marion Roussel, Inc. 3,004,436 (1) 10.5%
Route 202-206
Bridgewater, NJ 08807-0800
BB Biotech A.G. 2,293,000 (2) 8.0
c/o Bellevue Asset Management A.G.
Grunstrasse 12 CH-6343
Rothreuz, Switzerland
HFTP Investment LLC 2,194,185 (3) 7.7
c/o Promethean Investment Group, L.L.C.
40 West 57th Street, Suite 1520
New York, NY 10019
Brown Simpson Strategic Growth Fund, Ltd. 950,813 (4) 3.3
152 West 57th Street, 40th Floor
New York, NY 10019
Brown Simpson Strategic Growth Fund, L.P. 511,976 (5) 1.8
152 West 57th Street, 40th Floor
New York, NY 10019
Harvey J. Berger, M.D. 1,445,247 (6) 5.0
c/o ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA 02139
Jay R. LaMarche 312,109 (7) 1.1
Manfred Weigele, Ph.D. 261,410 (8) 1.0
Joan S. Brugge, Ph.D. 347,838 (9) 1.2
Vaughn D. Bryson 80,000 (10) *
</TABLE>
9
<PAGE> 11
<TABLE>
<S> <C> <C>
John M. Deutch, Ph.D. 74,553 (11) *
Philip Felig, M.D. 110,714 (12) *
Joel S. Marcus 80,000 (13) *
Sandford D. Smith 96,205 (14) *
Ralph Snyderman, M.D. 93,750 (15) *
Raymond S. Troubh 106,249 (16) *
Michael Gilman, Ph.D. 0 --
Charles C. Cabot III 143,857 *
All directors and executive officers
as a group (16 persons) 3,278,861 (17) 10.9
</TABLE>
- ----------
* Indicates less than one percent
(1) Includes 3,004,436 shares of Series B Preferred Stock convertible into
2,194,185 shares of Common Stock sold to Hoechst Marion Roussel, Inc. in
connection with the joint venture agreement for establishing and operating
the Hoechst-ARIAD Genomics Center, LLC and represents 100% of the Series B
Preferred Stock.
(2) Such shares are held of record by Biotech Target S.A., a wholly owned
subsidiary of BB Biotech A.G. This information is based solely on review of
Schedules 13D and 13G, each of which was filed with the Commission on May
28, 1998.
(3) Includes 3,000 shares of Series C Preferred Stock convertible into
2,194,185 shares of Common Stock and represents 60% of the Series C
Preferred Stock. Promethean Investment Group, LLC, a New York limited
liability company ("Promethean"), serves as investment advisor to HFTP
Investment, L.L.C. ("HFTP") and may be deemed to share beneficial ownership
of the shares beneficially owned by HFTP by reason of shared power to vote
and to dispose of the shares beneficially owned by HFTP. Promethean
disclaims beneficial ownership of the shares beneficially owned by HFTP.
Mr. James F. O'Brien, Jr. indirectly controls Promethean. Mr. O'Brien
disclaims beneficial ownership of the shares beneficially owned by
Promethean and HFTP.
(4) Includes 1,300 shares of Series C Preferred Stock convertible into 950,813
shares of Common Stock and represents 26% of the Series C Preferred Stock.
Brown Simpson Asset Management, L.L.C. serves as the investment manager to
Brown Simpson Strategic Growth Fund, Ltd. pursuant to an investment
management contract. The members of Brown Simpson Asset Management, L.L.C.
are Mitchell Kaye, Evan Levine, James Simpson and Matthew Brown. Such
persons may be deemed to have beneficial ownership of the shares owned by
Brown Simpson Strategic Growth Fund Ltd.
(5) Includes 700 shares of Series C Preferred Stock convertible into 511,976
shares of Common Stock and represents 14% of the Series C Preferred Stock.
The general partner of Brown Simpson Strategic Growth Fund, L.P. is Brown
Simpson Capital, L.L.C., the members of which are Mitchell Kaye, Evan
Levine, James Simpson and Matthew Brown. Such members may be deemed to have
beneficial ownership of the shares owned by Brown Simpson Strategic Growth
Fund, L.P.
(6) Includes 119,000 shares issuable upon exercise of stock options within 60
days of April 23, 1999. Includes 10,000 shares issuable upon exercise of
warrants within 60 days of April 23, 1999. Includes 535,714 shares of
Common Stock and 235,714 shares issuable upon exercise of stock options
within 60 days of April 23, 1999 held of record by The Berger Family Trust
and 8,928 shares of Common Stock held of record by The Wolk Family Trust.
Wendy S. Berger and Harvey J. Berger, as co-trustees of such trusts, have
the right to vote and dispose of the shares held by such trusts; however,
in certain circumstances, Wendy S. Berger as co-trustee will have sole
voting power with respect to the shares held by each such trust. Includes
122,000 shares held by Edith Berger, Dr. Berger's mother, 40,892 shares
held by Wendy S. Berger, Dr. Berger's spouse, and 11,928 shares held by Dr.
Berger's children.
(7) Includes 105,857 shares issuable upon exercise of stock options within 60
days of April 23, 1999. Includes 6,696 shares and 44,000 shares issuable
upon exercise of warrants within 60 days of April 23, 1999 held by Carol B.
LaMarche, Mr. LaMarche's spouse.
(8) Includes 111,857 shares issuable upon exercise of stock options within 60
days of April 23, 1999.
(9) Includes 154,714 shares issuable upon exercise of stock options within 60
days of April 23, 1999. Includes 6,696 shares held jointly by Dr. Brugge
and her spouse, William R. Brugge, M.D., and 9,773 shares held by her son.
(10) Includes 37,500 shares issuable upon exercise of stock options within 60
days of April 23, 1999.
(11) Includes 57,857 shares issuable upon exercise of stock options within 60
days of April 23, 1999.
(12) Includes 110,714 shares issuable upon exercise of stock options within 60
days of April 23, 1999.
(13) Includes 70,000 shares issuable upon exercise of stock options within 60
days of April 23, 1999.
(14) Includes 92,857 shares issuable upon exercise of stock options within 60
days of April 23, 1999.
(15) Includes 58,036 shares issuable upon exercise of stock options within 60
days of April 23, 1999.
(16) Includes 92,857 shares issuable upon exercise of stock options within 60
days of April 23, 1999.
(17) Includes the shares identified in footnotes (3) through (13) above, 421
shares held by John D. Iuliucci, and 94,178 and 124,928 shares issuable
upon exercise of stock options within 60 days of April 23, 1999 held by Dr.
Iuliucci and Mark J. Zoller, respectively.
10
<PAGE> 12
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
In March 1997, the Company entered into an agreement which established the
Hoechst-ARIAD Genomics Center, LLC, a Delaware limited liability company (the
"Genomics Center") which is owned 50% by ARIAD and 50% by Hoechst Marion
Roussel, Inc. ("HMR"), a greater than 5% holder of the Company's Voting
Securities, to pursue functional genomics (the "1997 HMR Genomics Agreement").
Under the terms of the 1997 HMR Genomics Agreement, the Company and HMR agreed
to commit $85,000,000 to the establishment of the Genomics Center and its first
five years of operation. Through December 31, 1998, the Company had invested
$6,500,000 in leasehold improvements and equipment and funded $8,839,000 in
operating and related costs. HMR has committed to provide ARIAD with capital
adequate to fund ARIAD's share of such costs through the purchase of up to
$49,000,000 of ARIAD Series B Preferred Stock over the five-year period,
including an initial investment of $24,000,000, which was completed in March
1997 and a subsequent investment of $5,747,000 which was completed in January
1999. Should ARIAD and HMR determine that the Genomics Center requires funds in
excess of those committed, ARIAD may fund its share of the excess through a loan
facility made available by HMR. Funds borrowed by ARIAD pursuant to such loan
facility, if any, will bear interest at a rate of LIBOR plus 0.25% and are
repayable by June 2003 in cash or Series B Preferred Stock, at the Company's
option.
The Company also entered into agreements with the Genomics Center to
provide research and administrative services (the "Services Agreements") to the
Genomics Center on a cost reimbursement basis. Revenue recognized pursuant to
the Services Agreements amounted to $4,951,000 and $1,357,000 for the years
ended December 31, 1998 and 1997, respectively.
In November 1995, the Company entered into an agreement with HMR (the "1995
HMR Osteoporosis Agreement") to collaborate on the discovery and development of
drugs to treat osteoporosis and related bone diseases, one of the Company's
signal transduction drug discovery programs. Under the 1995 HMR Osteoporosis
Agreement, the Company granted to HMR exclusive rights to develop and
commercialize these drugs worldwide. The Company has the right, under certain
circumstances, to participate in the development and commercialization of these
products for certain indications in North America. Under the terms of the 1995
HMR Osteoporosis Agreement, HMR made an initial cash payment to the Company of
$10,000,000, agreed to provide research funding in equal quarterly amounts of
$1,000,000 up to an aggregate of $20,000,000 over a five-year period and agreed
to provide an aggregate of up to $10,000,000 upon the attainment of certain
research milestones. In addition, HMR established a dedicated research group to
collaborate with the Company on the discovery of osteoporosis drugs and agreed
to fund all of the preclinical and clinical development costs for products that
emerge from the collaboration. The 1995 HMR Osteoporosis Agreement further
provides for the payment of royalties to the Company based on product sales.
Revenue recognized under the 1995 HMR Osteoporosis Agreement amounted to
$6,778,000, $7,333,000 and $9,333,000 for 1998, 1997 and 1996, respectively,
including, in 1996, $2,000,000 for the achievement of the first research
milestone. A second research milestone was achieved in February 1999, resulting
in a cash payment of $2,000,000.
11
<PAGE> 13
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this Amendment to be signed on its
behalf by the undersigned, thereunto duly authorized, this 30th day of April,
1999.
ARIAD PHARMACEUTICALS, INC.
(Registrant)
By: /s/ Jay R. LaMarche
----------------------------------
Jay R. LaMarche
Chief Financial Officer
12
